✦ LIBER ✦

Intravesical therapy in superficial bladder cancer

✍ Scribed by J.A. Witjes; P.F.A. Mulders; F.M.J. Debruyne

Book ID: 119047551
Publisher: Elsevier Science
Year: 1994
Tongue: English
Weight: 553 KB
Volume: 43
Category: Article
ISSN: 0090-4295
DOI: 10.1016/0090-4295(94)90211-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Bacillus Calmette-Guérin versus mitomyci

Bacillus Calmette-Guérin versus mitomycin intravesical therapy in superficial bladder cancer: Results of randomized trial after 21 months of follow-up

✍ F.M.J. DeBruyne; P.M. van der Meijden; J.A. Witjes; M.P.H. Franssen; P.A. Steere 📂 Article 📅 1992 🏛 Elsevier Science 🌐 English ⚖ 617 KB

Urinary interleukins in patients receivi

Urinary interleukins in patients receiving intravesical bacillus calmette-guerin therapy for superficial bladder cancer

✍ Jonathan D. Fleischmann; Zahra Toossi; Jerrold J. Ellner; Deborah B. Wentworth; 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 668 KB

## Intravesical administration of Bacillus Calmette-Guerin (BCG) causes a localized cell-mediated immune response. The intensity of this inflammatory response may be gauged by measuring the levels of both interleukin-2 (IL-2) and an inhibitor of interleukin-2 (IL-2-IN) activity in the urine during

Prophylactic intravesical instillation t

Prophylactic intravesical instillation therapy with adriamycin and mitomycin C in patients with superficial bladder cancer

✍ Tomoyasu Tsushima; Yosuke Matsumura; Yujiro Ozaki; Jun Yoshimoto; Hiroyuki Ohmor 📂 Article 📅 1987 🏛 Springer 🌐 English ⚖ 380 KB

Intravesical instillation of adriamycin (ADM) or mitomycin C (MMC) was carried out for the purpose of preventing the recurrence of superficial bladder cancers (Ta and T1) after transurethral resection or transurethral coagulation. First, eligible patients were divided into two groups (solitary and m

Prospective randomized comparison of int

Prospective randomized comparison of intravesical BCG therapy with standard dose versus low doses in superficial bladder cancer

✍ F. Yalçinkaya; L. Kamiş; O. Özteke; B. Günlüsoy; O. Yiĝitbasi; S. Ünal 📂 Article 📅 1998 🏛 Springer Netherlands 🌐 English ⚖ 192 KB

Risk of continued intravesical therapy a

Risk of continued intravesical therapy and delayed cystectomy in BCG-refractory superficial bladder cancer: an investigational approach

✍ Lorenzo G Luciani; Endre Neulander; William M Murphy; Zev Wajsman 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 120 KB

Total cystectomy after intravesical baci

Total cystectomy after intravesical bacillus Calmette-Guérin (Tokyo strain) therapy for superficial bladder cancer: Experience in Japan

✍ M. Takashi; A. Kondo; Y. Nakano; Y. Takagi; T. Sakata; K. Miyake 📂 Article 📅 1994 🏛 Springer Netherlands 🌐 English ⚖ 549 KB